GlassScriptPhysician profile
Taressa Stanton
NPI 1821351818
$4,836.58
in general payments reported to CMS, 2019-2025
27 companies · $1,460 in 2025
The $1,460 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $800 · 2022: $469 · 2023: $728 · 2024: $1,379 · 2025: $1,460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,467 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,467.25 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $783.88 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $677.37 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $646.82 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $472.15 | 2021-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $377.37 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $275.26 | 2023-2025 | |
| Pfizer INC. | $253.90 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $200.99 | 2021-2025 | Jardiance |
| Astellas Pharma US INC | $151.98 | 2024-2025 | Veozah |
| Phathom Pharmaceuticals, INC. | $130.57 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $121.17 | 2023-2024 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $98.34 | 2023-2025 | |
| Exact Sciences Corporation | $89.69 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sumitomo Pharma America, INC. | $86.48 | 2025 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $67.58 | 2025 | Caplyta |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $67.11 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.82 | 2021-2023 | Trintellix |
| Lexicon Pharmaceuticals, INC. | $48.64 | 2024 | |
| Mylan Specialty L.P. | $46.59 | 2023-2024 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $40.11 | 2024 | Eliquis |
| Gilead Sciences, INC. | $35.29 | 2024-2025 | |
| Viatris Specialty LLC | $25.89 | 2025 | Yupelri |
| Sanofi Pasteur INC. | $24.53 | 2023 | |
| Idorsia Pharmaceuticals US INC | $20.64 | 2023 | Quviviq |
| Edwards Lifesciences Corporation | $17.41 | 2021 | |
| Shield Therapeutics INC | $15.21 | 2025 | |
| Vertos Medical, INC. | $11.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taressa Stanton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.